Jie Wang
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 153
- Cancer Immunotherapy and Biomarkers 61
- Lung Cancer Research Studies 38
- CAR-T cell therapy research 11
-
- Lung Cancer Treatments and Mutations 74
- Lung Cancer Diagnosis and Treatment 18
- Co-authors
- Zhijie Wang (71 shared papers)Hua Bai (26 shared papers)Jianchun Duan (33 shared papers)Jie He (9 shared papers)Kailun Fei (19 shared papers)Hua Bai (33 shared papers)Jianchun Duan (31 shared papers)Jiachen Xu (23 shared papers)
- Journals
- Journal of Thoracic Oncology (13 papers)Frontiers in Oncology (11 papers)Frontiers in Immunology (10 papers)Translational Lung Cancer Research (8 papers)Scientific Reports (7 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Jie Wang
342 papers receiving 14.1k citations
Jie Wang's Hit Papers
Peers
Comparison fields: 5 of 153
- Oncology 6.4k
- Pulmonary and Respiratory Medicine 6.1k
- Cancer Research 1.7k
- Immunology 1.0k
- Molecular Biology 2.8k
Countries citing papers authored by Jie Wang
This map shows the geographic impact of Jie Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Wang more than expected).
Fields of papers citing papers by Jie Wang
This network shows the impact of papers produced by Jie Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Wang. The network helps show where Jie Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Jie Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 363 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Hit paper breakdown → | 2011 | 3516 |
| 2 | 2019 | 380 | |
| 3 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Hit paper breakdown → | 2015 | 351 |
| 4 | Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC Hit paper breakdown → | 2020 | 334 |
| 5 | 2019 | 302 | |
| 6 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 299 |
| 7 | 2019 | 289 | |
| 8 | Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 285 |
| 9 | 2013 | 257 | |
| 10 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial Hit paper breakdown → | 2023 | 256 |
| 11 | 2017 | 218 | |
| 12 | 2019 | 209 | |
| 13 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial Hit paper breakdown → | 2021 | 203 |
| 14 | 2018 | 199 | |
| 15 | 2012 | 195 | |
| 16 | Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis Hit paper breakdown → | 2021 | 195 |
| 17 | 2018 | 186 | |
| 18 | 2021 | 160 | |
| 19 | Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) Hit paper breakdown → | 2022 | 136 |
| 20 | 2010 | 126 |
About Jie Wang
Jie Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 363 papers that have together received 14.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (74 papers), Cancer Immunotherapy and Biomarkers (61 papers), Lung Cancer Research Studies (38 papers), Lung Cancer Diagnosis and Treatment (18 papers), Cancer Genomics and Diagnostics (17 papers), Gut microbiota and health (14 papers), Immunotherapy and Immune Responses (12 papers) and CAR-T cell therapy research (11 papers). The work is most often cited by research in Oncology (6.4k citations), Pulmonary and Respiratory Medicine (6.1k citations), Cancer Research (1.7k citations), Immunology (1.0k citations) and Molecular Biology (2.8k citations). Jie Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Zhijie Wang, Hua Bai, Jianchun Duan, Jie He, Kailun Fei, Hua Bai, Jianchun Duan, Jiachen Xu, Ying Cheng and Jianying Zhou. Their work appears in journals such as Journal of Thoracic Oncology, Frontiers in Oncology, Frontiers in Immunology, Translational Lung Cancer Research and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.